Advertisement

Topical Timolol Solution for Infantile Hemangioma of the Eyelid

Summary and Comment |
March 26, 2010

Topical Timolol Solution for Infantile Hemangioma of the Eyelid

  1. Mary Wu Chang, MD

For thin hemangiomas, at least, this topical beta-blocker may be safe and effective.

  1. Mary Wu Chang, MD

Infantile hemangiomas located near the eye may cause amblyopia, astigmatism, proptosis, ptosis, permanent visual impairment, and even blindness. Until recently, oral corticosteroids have been the standard treatment. Less commonly used options include intralesional corticosteroids, interferon alpha 2a, laser, embolization, immunomodulators, and surgery. Since the off-label use of systemic propranolol for infantile hemangiomas was first reported (JW Dermatol Jun 20 2008), its use in hemangioma treatment has grown. However, all systemic therapies for hemangiomas carry risks for adverse effects (JW Dermatol Nov 6 2009). Some investigators have focused on the use of another beta-blocker, timolol. Timolol solution is the most commonly prescribed therapy for childhood glaucoma; this is the first report of timolol used for periocular hemangioma.

The authors describe a 4-month-old girl with a thin-plaque hemangioma on the upper eyelid that caused blepharoptosis, occlusion of the pupil, and decreased visual function. The ophthalmologist prescribed timolol solution, applied topically by the mother's fingertip twice daily to the surface of the hemangioma. No systemic medication was given. After 5 weeks, the hemangioma was significantly reduced in size, thickness, and color, and the visual axis was unobstructed. Topical timolol was discontinued at 7 weeks. At 11 weeks, improved visual function was documented. There were no adverse effects.

Comment

The prospect of a safe and effective topical medication for superficial hemangiomas has long been enticing. High-potency topical steroids and topical imiquimod have been tried, with mixed results; these agents are not recommended if vision is compromised and rapid therapeutic response is needed. A dermatologic clinical trial studying topical timolol solution for cutaneous hemangiomas is currently underway. At the 35th annual meeting of the Society for Pediatric Dermatology, the promising, although not universal, success of topical timolol gel for periocular hemangiomas was discussed. I suspect that thickness, depth, and extent of the hemangioma and limitations of percutaneous drug absorption may influence the efficacy of topical beta-blocker therapy. However, a subset of thin hemangiomas may prove to respond beautifully, as in this case report. The results of these studies will be highly anticipated.

Citation(s):

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement